Seeking Alpha
13 Jun 2026, 16:23 UTC · 2h ago
Lyell Immunopharma: Undervalued Ahead Of A Major CAR-T Inflection
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
Seeking Alpha
13 Jun 2026, 16:23 UTC · 2h ago
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
What the story claims
3 claims · each scored for market impact
Lyell Immunopharma expects to release PiNACLE trial data for ronde-cel in the second half of 2026. — Pivotal trial data is a primary binary catalyst for biotech valuations and regulatory approval paths.
+0.80Lyell Immunopharma has a cash runway extending through the third quarter of 2027. — Sufficient liquidity reduces the immediate risk of dilutive financing and provides stability until major data readouts.
+0.40The company's lead candidate, ronde-cel, utilizes dual CD19/CD20 targeting and CD62L+ enrichment to treat relapsed/refractory LBCL. — Technological differentiation in safety and durability could provide a competitive advantage over existing CAR-T therapies.
+0.30Which stocks this story touches
Continue reading
6 related stories
Top 3 movers · tap to explore
The analyst views the company as undervalued with asymmetric upside and strong efficacy signals for its CAR-T pipeline.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
How the impact breaks down
Where the story's weight lands
Stocks most exposed
Modeled from each name's sensitivity to this story
No stock impact ranking available yet.
